Overview

The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol

Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.
Details
Lead Sponsor:
Alexion Pharmaceuticals
Treatments:
Eculizumab